ZFIN Fish: la2Tg

ZFIN ID: ZDB-FISH-150901-21121

ZFIN ID: ZDB-FISH-150901-21121

Fish name:	la2Tg
Genotype:	la2Tg
Targeting Reagent:	none

HUMAN DISEASE MODELED by la2Tg

Human Disease	Conditions	Citations
nephrotic syndrome	chemical treatment by environment: doxorubicin	Eneman et al., 2017

GENE EXPRESSION
Gene expression in la2Tg

RNA expression

Expressed Gene	Structure	Conditions	Figures
adcyap1a	whole organism	chemical treatment by environment: doxorubicin	Fig. S2 from Eneman et al., 2017
drl	thrombocyte	standard conditions	Fig. 1 from Pimtong et al., 2014
drll.1	thrombocyte	standard conditions	Fig. 1 from Pimtong et al., 2014
drll.2	thrombocyte	standard conditions	Fig. 1 from Pimtong et al., 2014
drll.3	thrombocyte	standard conditions	Fig. 1 from Pimtong et al., 2014
gata1a	intermediate cell mass of mesoderm	control	Fig. 3 from Louwette et al., 2012
itga2b	thrombocyte whole organism	standard conditions	Fig. 5 from Cooney et al., 2013 Fig. 2 from Tournoij et al., 2010 Fig. 3 from Woo et al., 2008
mpl	whole organism	standard conditions	Fig. 3 from Woo et al., 2008
myb	hematopoietic stem cell intermediate cell mass of mesoderm ventral wall of dorsal aorta	standard conditions	Fig. 4 from Cvejic et al., 2011 Fig. 7 from Bertrand et al., 2008
mylka	thrombocyte	standard conditions	Fig. 2 from Tournoij et al., 2010
nphs1	whole organism	chemical treatment by environment: doxorubicin	Fig. 5 from Eneman et al., 2017
tal1	intermediate cell mass of mesoderm	control	Fig. 3 from Louwette et al., 2012
znf148	whole organism	standard conditions	Fig. 3 from Woo et al., 2008

Protein expression

Antibody	Structure	Conditions	Figures
Ab1-pdgfb	thrombocyte	physical alteration: anatomical structure	Fig. S2 from Kim et al., 2010
Ab2-fn	ventral wall of dorsal aorta extracellular matrix	control	Fig. 4 from Theodore et al., 2017
Ab1-atp1a1	pronephric duct	control	Fig. 4 from Zhang et al., 2015

Reporter gene expression

Expressed Gene	Structure	Conditions	Figures
EGFP	blood cell caudal hematopoietic tissue thromboblast caudal vein plexus common cardinal vein dorsal aorta hematopoietic multipotent progenitor cell hematopoietic stem cell hematopoietic system posterior region intermediate cell mass of mesoderm hematopoietic multipotent progenitor cell kidney (not) myeloid cell myeloid lineage restricted progenitor cell (not) nucleate erythrocyte pharyngeal arch pigment cell post-vent region posterior cardinal vein primary head sinus pro-T cell pronephric duct pronephros cell thromboblast thrombocyte thymus thrombocyte thymus primordium ventral wall of dorsal aorta whole organism	standard conditions	70 figures from 41 publications
	hematopoietic stem cell intermediate cell mass of mesoderm hematopoietic stem cell thrombocyte	chemical treatment: pharmaceutical	Fig. 7 from Eneman et al., 2017 Fig. 3 from Lin et al., 2017 Fig. 5 from Yang et al., 2016 Fig. 2 , Fig. 6 from Esain et al., 2015 Fig. 6 from Bielczyk-Maczyńska et al., 2014 Fig. 1 from Harris et al., 2013
	thrombocyte	light damage: posterior caudal vein	Figure 2 from Fish et al., 2021 Fig. 4 from Lin et al., 2017 Fig. S2 from Kim et al., 2010
GFP	hematopoietic multipotent progenitor cell hematopoietic stem cell thrombocyte	standard conditions	Fig. 2 from Svoboda et al., 2014

PHENOTYPE
Phenotype in la2Tg

Phenotype	Conditions	Figures
caudal hematopoietic tissue hematopoietic stem cell decreased amount, abnormal	standard conditions	Fig. 3 from Oo et al., 2017
glomerular filtration process quality, abnormal	chemical treatment by environment: doxorubicin	Fig. 5 from Eneman et al., 2017
hematopoietic stem cell decreased amount, abnormal	chemical treatment by environment: 17beta-estradiol	Fig. 1 , Fig. 7 from Carroll et al., 2014
hematopoietic stem cell increased amount, abnormal	chemical treatment by environment: estrogen receptor antagonist	Fig. 7 from Carroll et al., 2014
hemostasis increased duration, abnormal	contusion: caudal fin	Fig. 4 from Lin et al., 2017
hemostasis increased duration, abnormal	perforation: blood vessel	Fig. 4 from Lin et al., 2017
intermediate cell mass of mesoderm hematopoietic stem cell decreased amount, abnormal	chemical treatment: cannabinoid receptor agonist	Fig. 2 from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell decreased amount, abnormal	chemical treatment: 3-[7-(2,4-dimethoxyphenyl)-1,4-thiazepan-5-ylidene]-6-methylpyran-2,4-dione	Fig. 6 from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell decreased amount, abnormal	chemical treatment: cannabinoid receptor agonist, chemical treatment: 3-[7-(2,4-dimethoxyphenyl)-1,4-thiazepan-5-ylidene]-6-methylpyran-2,4-dione	Fig. 6 from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell increased amount, abnormal	chemical treatment: cannabinoid receptor agonist, chemical treatment: EC 2.7.11.* (protein-serine/threonine kinase) inhibitor	Fig. 5 from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell increased amount, abnormal	chemical treatment: cannabinoid receptor agonist, chemical treatment: NS-398	Fig. 5 from Esain et al., 2015
intermediate cell mass of mesoderm hematopoietic stem cell increased amount, abnormal	chemical treatment: cannabinoid receptor agonist	Fig. 2 , Fig. 5 , Fig. 6 from Esain et al., 2015
pericardium edematous, abnormal	chemical treatment by environment: doxorubicin	Fig. 5 , Fig. 8 from Eneman et al., 2017
posterior caudal vein blood coagulation, fibrin clot formation normal process quality, normal	standard conditions	Fig. 5 from Freire et al., 2020
posterior caudal vein platelet aggregation normal process quality, normal	standard conditions	Fig. 5 from Freire et al., 2020
thrombocyte amount, normal	chemical treatment by environment: doxorubicin	Fig. 7 from Eneman et al., 2017
thrombocyte decreased amount, abnormal	chemical treatment: pharmaceutical	Fig. 6 from Bielczyk-Maczyńska et al., 2014
thrombocyte decreased amount, abnormal	chemical treatment by environment: TG101209	Fig. 3 from Lin et al., 2017
whole organism dead, abnormal	chemical treatment by environment: doxorubicin	Fig. 5 , Fig. 8 from Eneman et al., 2017
whole organism adcyap1a expression decreased amount, abnormal	chemical treatment by environment: doxorubicin	Fig. S2 from Eneman et al., 2017
whole organism nphs1 expression decreased amount, abnormal	chemical treatment by environment: doxorubicin	Fig. 5 from Eneman et al., 2017
whole organism morphology, abnormal	chemical treatment by environment: doxorubicin	Fig. 5 , Fig. 8 from Eneman et al., 2017

CITATIONS (96)